Maintained Benefit in Health-Related Quality of Life of Patients with Giant Cell Arteritis Treated with Tocilizumab Plus Prednisone Tapering: Results from the Open-Label, Long-Term Extension of a Phase 3 Randomized Controlled Trial

Stone J, Han J, Unizony S, Aringer M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, Rech J, Salvarani C, Spiera R, Bao M (2019)

Publication Type: Conference contribution

Publication year: 2019

Journal

Arthritis and Rheumatology Wiley

Publisher: WILEY

City/Town: HOBOKEN

Conference Proceedings Title: ARTHRITIS & RHEUMATOLOGY

Authors with CRIS profile

Hans Jürgen Rech Department of Medicine 3 – Rheumatology and Immunology

Involved external institutions

Harvard University

United States (USA) (US) Genentech Inc.

United States (USA) (US) National Health Service (NHS)

United Kingdom (GB) Technische Universität Dresden

Germany (DE) University Hospital Leuven (UZ) / Universitaire ziekenhuizen Leuven

Belgium (BE) University of Groningen / Rijksuniversiteit Groningen

Netherlands (NL) Universitat de Barcelona (UB) / University of Barcelona

Spain (ES) Arcispedale Santa Maria Nuova

Italy (IT) Hospital for Special Surgery (HSS)

United States (USA) (US)

How to cite

APA:

Stone, J., Han, J., Unizony, S., Aringer, M., Blockmans, D., Brouwer, E.,... Bao, M. (2019). Maintained Benefit in Health-Related Quality of Life of Patients with Giant Cell Arteritis Treated with Tocilizumab Plus Prednisone Tapering: Results from the Open-Label, Long-Term Extension of a Phase 3 Randomized Controlled Trial. In ARTHRITIS & RHEUMATOLOGY. HOBOKEN: WILEY.

MLA:

Stone, John, et al. "Maintained Benefit in Health-Related Quality of Life of Patients with Giant Cell Arteritis Treated with Tocilizumab Plus Prednisone Tapering: Results from the Open-Label, Long-Term Extension of a Phase 3 Randomized Controlled Trial." Proceedings of the ARTHRITIS & RHEUMATOLOGY HOBOKEN: WILEY, 2019.

BibTeX: Download